We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (... Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. Show more
Ask ADVFN Intelligence (AI)
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune...
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK®...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.27 | -2.45901639344 | 10.98 | 11.32 | 9.98 | 45690 | 10.61255952 | CS |
| 4 | -2.16 | -16.7832167832 | 12.87 | 13.14 | 9.68 | 66284 | 11.2564927 | CS |
| 12 | -5.13 | -32.3863636364 | 15.84 | 16.87 | 9.68 | 62766 | 11.85505664 | CS |
| 26 | -5.29 | -33.0625 | 16 | 17.31 | 9.68 | 121077 | 12.07786827 | CS |
| 52 | -5.29 | -33.0625 | 16 | 17.31 | 9.68 | 121077 | 12.07786827 | CS |
| 156 | -5.29 | -33.0625 | 16 | 17.31 | 9.68 | 121077 | 12.07786827 | CS |
| 260 | -5.29 | -33.0625 | 16 | 17.31 | 9.68 | 121077 | 12.07786827 | CS |
Amigo Mike
17 seconds ago
Shawonsarker84
18 seconds ago
glenn1919
36 seconds ago
sumbuysumsell
37 seconds ago
m0n
40 seconds ago
diamondguru-one
40 seconds ago
benhor
41 seconds ago
Inspector Clouseau
43 seconds ago
LetGoodTimesRoll
46 seconds ago
koolmc
51 seconds ago
JusticeWillWin
53 seconds ago
Jetmek_03052
59 seconds ago
benhor
59 seconds ago
Penny Stocks 2.0
1 minute ago
Tahoe2468
1 minute ago
DjScottyT
1 minute ago
hummba
1 minute ago
in99flyers
1 minute ago
Coo breeze
1 minute ago
DiscoverGold
1 minute ago
PlaySmart2020
2 minutes ago
jbsliverer
2 minutes ago
GREGG THE GREEK
2 minutes ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
